Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 4176-4184

  Yoo, Byong Chul ^a   Jeon, Eunkyung ^a   Hong, Sung Hye ^b   Shin, Young Kyoung ^b   Chang, Hee Jin ^a   Park, Jae Gahb ^a,b  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 PHOSPHONOBUTYRIC ACID; AMINO 2 METHYL 4 PHOSPHONOBUTANOIC ACID; BUTYRIC ACID DERIVATIVE; CYCLIC AMP; FLUOROURACIL; GLUTAMATE RECEPTOR; METABOTROPIC RECEPTOR 4; PROTEIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

AMINO ACIDS; AMINOBUTYRIC ACIDS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EXCITATORY AMINO ACID AGONISTS; FLUOROURACIL; HUMANS; LIGANDS; PHOSPHONIC ACIDS; RECEPTORS, METABOTROPIC GLUTAMATE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 3042631054     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1114-03     Document Type: Article

References (38)

1. Ferlay J, Bray F, Pisani P, Parkin DN. GLOBOCAN 2000-cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC Cancer Base No. 5, Lyon: IARC Press; 2001.
2. Rabeneck L, El-Serag HB, Davila JA, Sandler RS. Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). Am J Gastroenterol 2003;98:471-7.
3. Blijham GH. Chemotherapy of colorectal cancer. Anticancer Drugs 1991;2:233-45.
4. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
5. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-9.
6. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
7. Herrmann R. 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol 1996;7:551-2.
8. Bertino JR. Biomodulation of 5-fluorouracil with antifolates. Semin Oncol 1997;24(5 Suppl 18):S18-56.
9. Chau I, Cunningham D. Chemotherapy in colorectal cancer: new options and new challenges. Br Med Bull 2002;64:159-80.
10. Royce ME, Medgyesy D, Zukowski TH, Dwivedy S, Hoff PM, Pazdur R. Colorectal cancer: chemotherapy treatment overview. Oncology (Huntingt) 2000;14:40-6.
11. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer (Phila) 1991;68:1903-9.
12. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-80.
13. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30A:1517-22.
14. Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
15. Bapat AR, Zarow C, Danenberg PV. Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem 1983;258:4130-6.
16. Berger SH, Barbour KW, Berger FG. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line. Mol Pharmacol 1988;34:480-4.
17. Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988;48:5894-900.
18. Mader RM, Muller M, Steger GG. Resistance to 5-fluorouracil. Gen Pharmacol 1998;31:661-6.
19. Oh JH, Ku JL, Yoon KA, et al. Establishment and characterization of 12 human colorectal-carcinoma cell lines. Int J Cancer 1999;81:902-10.
20. Kang MS, Kim HS, Han JA, Park SC, Kim WB, Park, J-G. Characteristics of human gastric carcinoma cell lines with induced multidrug resistance. Anticancer Res 1997;17:3531-6.
21. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
23. Langen H, Roder D, Juranville JF, Fountoulakis M. Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 1997;18:2085-90.
24. Fountoulakis M, Langen H. Identification of proteins by matrix-assisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal Biochem 1997;250:153-6.
25. Swiss-Prot/TrEMBL Search Results for mGluR4 〈http://tw.expasy.org/ cgi-bin/niceprot.pI?Q14833〉. Entered in Swiss-Prot, November 1, 1997.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 1970;227:680-5.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Knopfel T, Kuhn R, Allgeier H. Metabotropic glutamate receptors: novel targets for drug development. J Med Chem 1995;38:1417-26.
29. Thomsen C, Kristensen P, Mulvihill E, Haldeman B, Suzdak PD. L-2-Amino-4-phosphonobutyrate (L-AP4) is an agonist at the type IV metabotropic glutamate receptor which is negatively coupled to adenylate cyclase. Eur J Pharmacol 1992;227:361-2.
30. Tong Q, Ouedraogo R, Kirchgessner AL. Localization and function of group III metabotropic glutamate receptors in rat pancreatic islets. Am J Physiol Endocrinol Metab 2002;282:E1324-33.
31. Gill SS, Pulido OM, Mueller RW, McGuire PF. Immunochemical localization of the metabotropic glutamate receptors in the rat heart. Brain Res Bull 1999;48:143-6.
32. Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 2001;22:174-81.
33. Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34:108-12.
34. Sampaio LF, Paes-de-Carvalho R. Developmental regulation of group III metabotropic glutamate receptors modulating adenylate cyclase activity in the avian retina. Neurochem Int 1998;33:367-74.
35. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 2001;98:6372-7.
36. Cavalheiro EA, Olney JW. Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 2001;98:5947-8.
37. Borodezt K, D'Mello SR. Decreased expression of the metabotropic glutamate receptor-4 gene is associated with neuronal apoptosis J Neurosci Res 1998;53:531-41.
38. Taylor DL, Diemel LT, Pocock JM. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 2003;23:2150-60.